Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer

June 3, 2015 updated by: Xiaoming Xie

Impact of Breast-Conserving Therapy (BCT) on Recurrence in Patients With Triple-Negative Breast Cancer (TNBC) Compared With Mastectomy

RATIONALE: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR) and distant metastasis (DM). The equivalent impact of breast-conserving therapy (BCT) and mastectomy on disease-free survival in patients with early breast cancer has been established by a number of large randomized controlled trials and meta-analysis. However, ongoing dispute exists on whether TNBC is a good candidate for BCT.

PURPOSE: This prospective, randomized, open, single-center Phase III clinical study is conducted to compare efficacy and safety of breast-conserving therapy and mastectomy in treating Chinese patients with early TNBC.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

STUDY POPULATION:

Operable patients with T1-2N0-1M0 triple-negative breast cancer

OBJECTIVES:

Primary To assess the impact of breast-conserving therapy on disease-free survival compared with mastectomy in patients with T1-2N0-1M0 triple-negative breast cancer.

Secondary To assess the impact of breast-conserving therapy on locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) compared with mastectomy in patients with T1-2N0-1M0 triple-negative breast cancer.

OUTLINE:

This is a prospective, randomized, open, single-center Phase III clinical study.

Patients undergo either lumpectomy or mastectomy with surgical axillary staging with all lesions resected to negative margins based on the results of randomization generated by computer.

Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.

Since all tumors are smaller than 5cm and metastatic lymph nodes are less than 4, patients undergoing mastectomy do not receive radiation therapy. On the hand, within 4-8 weeks after completion of chemotherapy, patients undergoing breast-conserving surgery receive radiation therapy as follows: (1) N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.

After completion of study treatment, patients are followed up every 3 months for 2 years and then 6 months for years 3-5.

Study Type

Interventional

Enrollment (Anticipated)

464

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Female aged 18 - 65 years old;
  2. Staging of Cancer: cT1-2N0-1M0;
  3. Histological confirmed with unilateral invasive carcinoma (all pathological types are applicable);
  4. Definite reports on ER/PR/Her2 receptor showing all ER/PR/Her2 negative (specific definitions: immunohistochemical detection of ER <10% tumor cells is defined as ER negative, PR <10% positive tumor cells is defined as PR-negative, Her2 is 0~1+ or 2+ but determined negative via FISH or CISH detected (no amplification) is defined as Her2 negative);
  5. Newly diagnosed conditions allowing direct surgery without any absolute contraindication for surgery;
  6. ECOG performance score is 0 or 1;
  7. No mass or microscopic tumor residue after surgery resection;
  8. Informed consent form signed.
  9. Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study.

Exclusion Criteria:

  1. Bilateral breast cancer;
  2. Clinical or radiographic evidence of metastatic disease;
  3. Widespread disease that cannot be incorporated by local excision through a single incision that achieves negative margins with a satisfactory cosmetic result;
  4. Diffuse suspicious or malignant-appearing microcalcifications;
  5. Positive pathologic margin;
  6. Any of ER, PR or Her2 is positive;
  7. Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone therapy;
  8. Prior history of breast cancer or any other malignant disease (except for basal cell carcinoma and cervical carcinoma in situ);
  9. Severe systemic disease and/or uncontrollable infection, unable to be enrolled in this study;
  10. Known allergic to taxane and anthracycline agents;
  11. Pregnant and breast-feeding women;
  12. With mental illness and cognitive impairment, unable to understand trial protocol and side effects and complete trial protocol and follow-ups;
  13. Without personal freedom and independent civil capacity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Breast-Conserving Therapy
  1. Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.

  2. Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:

    TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.

    TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.

  3. Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:

N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
Procedure: Breast-Conserving Therapy
Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
Drug: Adjuvant Chemotherapy
Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
Radiation: Radiation Therapy
N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
ACTIVE_COMPARATOR: Mastectomy
  1. Patients undergo mastectomy (MT) with surgical axillary staging.
  2. Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:

TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.

TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.
Drug: Adjuvant Chemotherapy
Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
Procedure: Mastectomy
Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease-free survival(DFS)
Time Frame: Up to 5 years post-treatment
DFS is defined as time (measured in months) from initial local-regional surgical treatment until first recurrence (local or distant) or last follow-up.
Up to 5 years post-treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Locoregional recurrence-free survival(LRRFS)
Time Frame: Up to 5 years post-treatment
LRR refers to any progression in the breast/chest wall and/or regional lymph nodes.
Up to 5 years post-treatment
Distant metastasis (DM)
Time Frame: Up to 5 years post-treatment
DM is determined by clinical and radiographic means and/or histologically proven larger than 0.2mm.
Up to 5 years post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xiaoming Xie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (ANTICIPATED)

December 1, 2022

Study Registration Dates

First Submitted

June 1, 2015

First Submitted That Met QC Criteria

June 3, 2015

First Posted (ESTIMATE)

June 8, 2015

Study Record Updates

Last Update Posted (ESTIMATE)

June 8, 2015

Last Update Submitted That Met QC Criteria

June 3, 2015

Last Verified

June 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014-FXY-093

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Breast-Conserving Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe